Oral-modified release pharmaceutical composition for treating myasthenia gravis and rheumatoid arthritis, and reducing gastric irritation, comprises delayed release azathioprine particles, and excipient, where composition is in the form of suspension or dry formulation for reconstitution
	CHAUDHARI D V; BANSAL N K; NAGORI S A; KANERIA V T; MURTHY C R; MUTHAIYYAN K E
	2023-07-25
专利权人	ZYDUS LIFESCI LTD (CDLA-C)
申请日期	2023-07-25
专利号	IN202321049978-A
成果简介	NOVELTY - An oral-modified release pharmaceutical composition comprises delayed release azathioprine particles, and at least one excipient, where the composition is in the form of suspension or dry formulation for reconstitution. USE - Oral-modified release pharmaceutical composition for treating myasthenia gravis and rheumatoid arthritis, reducing gastric irritation, and preventing rejection in renal homotransplantation. Test details are described but no results given. ADVANTAGE - The modified release composition ensures improved patient convenience, reduced frequency for administration, and provides mean blood plasma Cmax of 10-120 ng/mL, and mean blood plasma AUC of 10-200 ng.hour/mL, when a dose of 10-200 mg azathioprine is orally administered, and allows convenient administration of azathioprine to children and geriatric patients with reduced gastrointestinal side effects of the drug.
IPC 分类号	A61K-031/52 ; A61K-031/585 ; A61P-025/00 ; A61P-029/00 ; C07J-073/00
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/21139
专题	中国科学院新疆生态与地理研究所
作者单位	ZYDUS LIFESCI LTD (CDLA-C)
推荐引用方式 GB/T 7714	CHAUDHARI D V,BANSAL N K,NAGORI S A,et al. Oral-modified release pharmaceutical composition for treating myasthenia gravis and rheumatoid arthritis, and reducing gastric irritation, comprises delayed release azathioprine particles, and excipient, where composition is in the form of suspension or dry formulation for reconstitution. IN202321049978-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。